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INTRODUCTION
Due to protracted clinical course of  prostate cancer 
(PCa), clinical guidelines recommend treatment in men 
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with life expectancy of more than 10 years. [1] Appropriate 
treatment of PCa is largely dependent on the preoperative 
risk of  disease progression among patients. Based on 
patient’s risk stratification, patients may be offered with 
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different treatment modalities. All of these factors should be 
considered in offering any intervention among patients with 
localized disease. Nowadays, due to the upstream availability 
of  minimally invasive options low risk PCa are likewise 
being offered with minimally invasive approach with the 
aid of robotic system.
In counseling, physicians rely mostly on biopsy Gleason 
score (GS) of their patients. Discordance between prostate 
biopsy and prostatectomy GS is not uncommon. Albertsen et 
al. [2] showed that men 55 to 74 years old with biopsy GS 6 
have 18% to 30% risk of dying from PCa in the next 15 years 
of their lives. It is estimated in previous literatures that 50% 
of needle biopsy score will be upgraded on final pathology 
specimen [3]. In our previous study, our results showed that 
patients treated with radical prostatectomy for clinically low 
risk disease has 12.9% to 36.4% chance of upgrading [4]. This 
inaccuracy has serious impact on pretreatment decision-
making, predominantly in patients who choose active 
surveillance or nonsurgical options. Increase in biopsy GS in 
men with pathological GS 8 to 10 put them on higher risk 
of death from PCa [5]. Likewise, upgrade in GS put them 
in increased chances of biochemical recurrence (BCR) [6,7]. 
Several articles involving patients treated with open radical 
prostatectomy have discussed the predictors of GS upgrading 
[6,8-10]. Nevertheless, no one among them reported the 
predictor of the degree of upgrading into higher pathologic 
GS (≥8). To the best of our knowledge this is the first study 
to report on the predictors of upgrading and the degree of 
upgrade exclusively on GS 6 patients treated with RARP.
In this study, we report predictors of GS upgrading and 
degree of upgrading among patients who have an initial GS 
6 biopsy treated with RARP.
MATERIALS AND METHODS
We retrospectively reviewed records from our prospec-
tively maintained Institutional Review Board-database 
(approval number: 2014-009-001) of patients who underwent 
RARP for PCa between July 2005 to June 2010. Patients 
with clinically localized PCa based on magnetic resonance 
imaging, digital rectal examination, are included in the 
study. Twelve-core transrectal ultrasound guided needle 
biopsy was done on all patients. After excluding patients 
with nonorgan confined PCa, Prostate-specific antigen 
(PSA)>20 ng/mL and patients with missing information 
needed to classify disease risk, 359 men with an initial 
biopsy GS of 6 were included in the study.
RARP was performed via a transperitoneal approach 
as described in our previous study [11], using the daVinci 
Surgical System (Intuitive Surgical, Sunnyvale, CA, USA) 
with the pelvic lymph node dissection being performed 
when predicted probability of lymph node metastasis based 
on clinical information is more than 3% [12].
Patients’ clinical and pathological variables: age, body 
mass index (BMI), prostate volume, PSA, number of core 
involvement, biopsy and prostatectomy GS were obtained. A 
dedicated pathologist evaluated the prostatectomy specimens 
with particular attention to pathologic stage, GS, surgical 
margins, perineural invasion and angiolymphatic invasion. 
GS upgrading is considered if initial biopsy GS≤6 increased 
on prostatectomy specimen to ≥GS 7 [13]. Patients were 
grouped into group 1 (nonupgrade GS) and group 2 (upgraded 
GS) and comparative analysis was performed. The primary 
aim was to evaluate the predictors of GS upgrading and its 
degree, meanwhile the secondary outcome was to evaluate 
the oncological outcomes of  upgraded GS degrees 7 (3+4, 
4+3), and ≥8.
Follow-up with physical examination and PSA quarterly 
for the first year, semiannually for the second year, and 
annually thereafter was done. BCR was defined as post-
operative PSA≥0.2 ng/mL taken twice at least 6 weeks apart 
[14].
Statistical analysis was used to analyze demographic 
and pathological characteristics. Counts of  frequencies 
were expressed as percentages, and continuous data were 
presented as mean±standard deviation (SD) or median and 
interquartile range (skewed data). Student t-test was used 
for continuous variables while chi-square test was used for 
categorical variables. The probability of BCR, Cancer specific 
survival (CSS) and overall survival (OS) among upgraded 
patients were calculated by the Kaplan-Meier analysis. The 
univariable and multivariable logistic regression models 
were used to estimate the impact of  clinical features 
on upgrading and degree of  upgrading. The IBM SPSS 
Statistics ver. 22.0 (IBM Co., Armonk, NY, USA) was used 
for all statistical analyses. A p-value of <0.05 was considered 
significant, and all p-values were 2-sided.
RESULTS
The mean age of the patient was 63 years old (SD, ±7.5). 
Mean BMI, prostate volume, and PSA were 24.2±2.6 kg/m2 
(interquartile range [IQR], 15.9–30.8 kg/m2), 39.2±20.9 (mL) 
(IQR, 10.5–164 mL), and 6.8 ng/mL (IQR, 5–10 ng/mL), respec-
tively. Our median follow-up was 59 months (IQR, 47–70 
months).
Table 1 summarized the comparative preoperative cha-




Patients in the upgraded group were older (p=0.007) and had 
higher PSA and smaller prostate in volume; 7.7 ng/mL (IQR, 
5.2–12.4 ng/mL) and 36.4±16.4 mL, respectively. The mean age 
of patients in the group 2 was 62.2±7.6 years while it was 
64.3±7.3 years for group 1 (p=0.007). Likewise, PSA density 
is higher in group 2 compared to group 1 with 0.30±0.28 and 
0.21±0.14, respectively. Among group 2 patients, 35.9% (52 of 
145) had a PSA of 10–20 compared to group 1 with 17.3%. 
Moreover, 77.2% (112 of 145) of group 2 patients had ≥2 core 
involvements. More than 25% positive core involvement was 
seen in 43.4% of patients who upgraded compared to 26.2% 
who did not upgrade (p=0.001). Group 2 patients had higher 
pathologic T stage with 44.1% having >T3 (p≤0.001). Positive 
surgical margin (PSM) was higher in upgraded group with 
compared to nonupgraded patients (p≤0.009). Significantly, 
perineural invasion was higher in upgraded group 51.7% 
versus 19.2% among the nonupgraded group (p≤0.001). Ten 
percent of group 2 patients showed angiolymphatic invasion 
compared to 2.3% of group 1 (p=0.002).
Table 2 summarized the comparison among upgraded 
patients. Patients who upgraded to Gleason score ≥8 had 
higher preoperative PSA (p=0.000). The results of  uni-
variable and multivariable logistic regression analyses were 
summarized in Table 3. Statistically significant preoperative 
variables were included in the regression model. Age, PSA, 
PSA density, clinical T stage, percentage of  cores and 
Table 1. Patients’ characteristics
Variable Nonupgrade (n=214) Upgrade (n=145) p-value
Age (y) 62.2±7.6 64.3±7.3 0.007a
Body mass index (kg/m2) 24.2±2.6 24.3±2.5 0.91a
PSA (ng/mL) 7.3±3.5 9.0±4.6 0.000a
Prostate volume (mL) 40.0±22.0 35.5±16.0 0.03a
PSA density 0.2±0.1 0.3±0.3 0.000a
Follow-up period (mo), median (IQR) 59 (50–71) 58 (41–61.5) 0.05a
Clinical T stage group 0.006b
   T1–T2a 161 (75.2) 95 (65.5)
   T2b–T2c 34 (15.9) 20 (13.8)
   >T3 19 (8.9) 30 (20.7)
Biopsy Gleason character positive core 0.02b
   1 74 (34.4) 33 (22.8)
   ≥2 140 (65.6) 112 (77.2)
Positive core involvement >25% 0.001b
   Yes 56 (26.2) 63 (43.4)
   No 158 (73.8) 82 (56.6)
Pathologic T stage <0.001b
   T2 182 (85.0) 81 (55.9)
   T3–4 32 (15.0) 64 (44.1)
Positive surgical margin 0.009b
   Positive 18 (8.4) 26 (17.9)
   Negative 196 (91.6) 119 (82.1)
Perineural invasion <0.001b
   Yes 41 (19.2) 75 (51.7)
   No 173 (80.8) 70 (48.3)
Angiolymphatic invasion 0.002b
   Yes 5 (2.3) 15 (10.3)
   No 209 (97.7) 130 (89.7)
Nerve sparing 0.69b
   No 37/154 (24.0) 22/113 (19.5)
   Unilateral 37/154 (24.0) 28/113 (24.8)
   Bilateral 80/154 (51.9) 63/113 (55.8)
Values are presented as mean±standard deviation or number (%) unless otherwise indicated.
PSA, prostate-specific antigen; IQR, interquartile range.
a:Based on Student t-test. b:Based on chi-square test.
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number of  positive had significant result hence further 
analyzed on regression analysis. Moreover, on multivariable 
analysis age, PSA, PSA density and >2 cores positive were 
predictors of  upgrading with (odds ratio [OR], 1.03; 95% 
confidence interval [CI], 1.01–1.06; p=0.003; OR, 1.006; 95% 
CI, 1.01–1.11; p=0.018; OR, 0.65; 95% CI, 0.43–0.98, p=0.04), 
respectively were strongest predictors of GS upgrade among 
clinicopathological variables.
On subanalysis of the predictors of degree of upgrading 
on Table 4, we found out that only PSA level of 10–20 is 
significantly associated with the degree of  upgrading to 
GS≥8 (p=0.000). Patients with upgraded GS 8 or more had 
lower rates of 5 years of BCR-free survival, CSS, and OS 
(p≤0.001, p=0.003, and p=0.01, respectively) (Figs. 1-3).
DISCUSSION
In this study, we have shown that patients preoperative 
PSA level of  10–20 ng/mL have increased likelihood of 
upgrading from GS 6 into pathologic GS≥8. Likewise, we 
report the predictors of  upgrading like age, PSA, PSA 
density, and number of  cores among patients who have 
solely GS 6 on needle biopsy. Knowledge on the impact of 
GS upgrading is of great importance especially at the point 
of shared decision-making between the physician and the 
patient prior to any planned intervention. In a study done 
by Carlsson et al. [15], they concluded that having surgery 
as primary treatment for low risk PCa might result in 
favorable oncologic outcome but may also jeopardize men’s 
Table 2. Comparison of upgraded Gleason score 6 patients
Variable 3+4 (n=87) 4+3 (n=37) ≥4+4 (n=18) p-value
Age (y) 63±7 65±7 65±9 0.26a
Body mass index (kg/m2) 23.8±2.4 24.6±2.1 24.6±3.0 0.16a
PSA (ng/mL) 8.0±3.9 8.3±3.8 13.1±4.8 0.000a
Prostate volume (mL) 36.0±17.2 36.3±15.0 36.0±16.0 0.19a
PSA density 0.25±0.13 0.25±0.18 0.23±0.15 0.72a
Core number 0.74b
   1 16 (19.8) 9 (25.7) 4 (23.5)
   ≥2 65 (80.2) 26 (74.3) 14 (76.5)
Percent positive core>25% 0.58b
   Yes 35 (43.2) 13 (37.1) 9 (52.9)
   No 46 (56.8) 22 (62.9) 8 (47.1)
Values are presented as mean±standard deviation or number (%).
PSA, prostate-specific antigen.
a:Based on Student t-test. b:Based on chi-square test.
Table 3. Logistic regression analysis of predictive factors associated with overall upgrading
Variable
Univariable Multivariable
OR 95% CI p-value OR 95% CI p-value
Age 1.03 1.01–1.06 0.005 1.03 1.01–1.06 0.003
PSA 1.09 1.05–1.13 0.000 1.006 1.01–1.11 0.018
PSA density 5.20 2.80–9.60 0.000 2.70 1.15–6.35 0.022
Prostate volume 0.99 0.98–1.00 0.212 - - -
Core number 0.020 0.04
   1 Reference - Reference -
   ≥2 0.62 0.41–0.92 0.65 0.43–0.98
Positive cores>25% 0.017 0.51
   No Reference - Reference -
   Yes 1.01 1.00–1.01 1.14 0.76–1.71
Clinical T stage
   T1–T2a Reference - 0.006 Reference - 0.30
   T2b–T2c 1.00 0.62–1.62 0.984 0.76 0.48–1.21 0.25
   >T3 1.92 1.27–2.91 0.002 0.63 0.34–1.14 0.13




potency and continent rate postoperatively. This scenario 
may have an impact on patients’ overall quality of  life 
and great importance is often placed during counseling. At 
this point, preoperative predictors of upgrading may help 
urologist in proper counseling of their patients. 
Previous reports have discussed that PSA level is a 
significant predictor of upgrading [16,17]. At some point the 
level of PSA to which upgrading is most likely to occur have 
been discussed by Colleselli et al. [18]. They reported that 
patients with PSA range of 2.0–3.9 and 4.0–10.0 ng/mL had 
a 32.6% and 44% risk of upgrading, respectively. Among the 
previously mentioned studies, no one has investigated on the 
predictor of the degree of upgrading among their cohorts. To 
our knowledge, our study is the first to discuss the predictor 
of the degree of upgrading on exclusively GS 6 patients on 
needle biopsy. 
Meanwhile, several studies have reported different 





Age 1.01 0.95–1.08 0.59
Body mass index 1.09 0.90–1.30 0.34
PSA 0.000
   <10 Reference -
   10–20 6.65 2.36–18.75
PSA density 0.48 0.02–11.75 0.65
Prostate volume 1.00 0.97–1.03 0.80
Core number 0.77
   1 Reference -
   ≥2 1.17 0.38–3.65
Positive cores>25% 0.31
   No Reference -
   Yes 0.61 0.23–1.58































Fig. 1. Upgraded patients’ biochemical recurrence (BCR)-free survival 




































































Fig. 3. Upgraded patients’ overall survival rate. GS, Gleason score.
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preoperative predictors of  upgrading. Hwang et al. [8], 
reported that not only PSA but percent positive biopsy core 
were predictors of  upgrading. However their study was 
limited to a small number of cohort. Similarly, Colleselli et al. 
[18] found out that tumors are likely to get upgraded when 
the number of biopsy cores was high even if their PSA is 
low. Greater than one core positive for cancer on needle 
biopsy is associated with increased chances of upgrading 
[9]. In the current study, we found out that patients with 
more than or equal to 2 cores involved had higher chances 
of  upgrading. This might be explained by the fact that 
presence of multiple cores increases the likelihood of lymph 
node invasion and less organ-confined disease (≥pT3). 
[19,20] Thus, even on patients with GS 6 on biopsy risk of 
upgrading is increased whenever multiple cores are present.
In a cohort of 2,771 men, the group of Serkin et al. [21] 
reported that patients with higher PSA density were likely 
to upgrade. And this could also happen even if  they are 
eligible for active surveillance [22]. In support to their find-
ings, PSA density was also a significant predictor of overall 
upgrading among our patients. However, when PSA density 
was entered on the model for predicting degree of upgrading 
it has lost its significance. This might be due to the small 
number of  patients who upgraded to ≥8. Meanwhile, 
prostate volume has long been a point of debate; several 
reports have stated that prostate volume is a significant 
predictor of  upgrading among patients who underwent 
radical prostatectomy [10,23,24]. There seems to be an inverse 
relationship between prostate size and chances of upgrading 
which was also evident in our current study.
On the other hand, patients’ age showed to have an 
impact on upgrading in our cohort. This may be explained 
by the fact that as man ages PSA level tends to increase 
stepwise. This was also evident in the cohort of  25,858 
patients reported by Caster et al. [25], that older age was 
associated with GS upgrading and pathologically advanced 
disease.
Difference between biopsy and prostatectomy specimen 
GS has a significant impact on BCR. Corcoran et al. [6] 
reported that change in GS on prostatectomy was a predictor 
of  BCR. Moreover, Boorjian et al. [5] also found out that 
upgrading in GS was associated with BCR and progression 
to systemic disease, though their study included all GS. 
Likewise, our findings suggest that BCR was notably higher 
among patients who upgraded into higher GS in support 
of the aforementioned studies. Badani et al. [26] reported 
in their series of 2,766 patients a BCR of 7.3% however its 
median follow-up was only 22 months. On the other hand, 
Menon et al. [7], did a study with a median follow-up of 60.2 
months however, their study included all GS. In our current 
study, we reported the oncologic outcome of our cohort at a 
median follow-up of 59 months for specifically GS 6 patients 
alone after RARP. This reflects a more realistic oncologic 
behaviour of patients who were initially GS 6 on biopsy but 
subsequently changed on pathologic specimen.
Upgraded group of patients have had significant diffe-
rences in PSM, extraprostatic extension, seminal vesicle 
invasion, and lymphovascular invasion [27]. Accordingly, 
the rate of extraprostatic extension, and PSM were noted to 
be higher among patients who have GS upgrading during 
radical prostatectomy [9]. In concordance, our results also 
showed that upgraded group had higher PSM, perineural 
invasion and angiolymphatic invasion compared to 
nonupgrade group depicting probably a more aggressive 
disease.
There are several limitations in our study. First of all, 
this study was analyzed in a retrospective manner. Small 
number of  patients which represents a higher degree 
of  upgrading from GS 6 is one of  its main limitation. 
Comparative analysis of patients with originally GS ≥8 from 
biopsy and those who upgraded from GS 6 to ≥8 is likewise 
recommended. A longer follow-up maybe needed to portray 
satisfactory oncologic impact of upgrading to clinical course 
and disease progression of  patients with initially GS 6 
treated with radical prostatectomy. Despite these limitations, 
our study showed that patients with higher preoperative 
PSA level has increased risk of upgrading to higher degree 
of GS which should be discussed thoroughly before offering 
any treatment options to patients.
CONCLUSIONS
Patients with GS 6 on biopsy with PSA level of 10–20 
ng/mL carries an increased risk of upgrading into higher 
pathologic GS (≥8) with poorer oncologic outcome. Presence 
of multiple cores, high PSA density increases the likelihood 
of upgrading. We recommend strict counseling especially in 
choosing treatment options between surgical and nonsurgical 
for patients with GS 6 on biopsy whenever these parameters 
are present.
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